Skip to main content

Table 2 Summary of the relationship between CDH13 methylation and bladder cancer

From: Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis

 

Studies

Overall OR (95 % CI)

I2; p

P value

Cases

Controls

p (Egger’s test)

Total

8

21.71 (9.83–47.94)

0.0 %; 0.495

<0.001

920

265

0.008

 Material:

  Urine

3

7.71 (2.65–22.39)

0.0 %; 0.831

<0.001

320

110

 

  Tissue

4

53.94 (12.83–226.87)

0.0 %; 0.986

<0.001

473

114

 

 Race:

  Caucasians

2

8.86 (2.91–27.03)

24.0 %; 0.251

<0.001

187

60

 

  Asians

6

35.18 (11.20–110.55)

0.0 %; 0.903

<0.001

733

205

 
  1. CDH13 H-cadherin, OR odds ratio, CI confidence interval
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us